Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MCAC Device Panel Chairman Sees Opportunity To Raise Clinical Standards

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Coverage Advisory Committee should demand the same standards of evidence as other established technology assessment programs, Medical Device and Prosthetics Panel Chairman Harold Sox, MD, Dartmouth-Hitchcock Medical Center maintains.

You may also be interested in...



One-Third Of HCFA DME Panel Appointees Backed By Congressmen

Three of the nine voting members named to the durable medical equipment panel of the Health Care Financing Administration's Medicare Coverage Advisory Committee received congressional support in their bid for appointment.

HCFA Names MCAC Diagnostic Imaging Panel, Sets Lab Services Panel Date

Jeffrey Lerner, PhD, VP-strategic planning, ECRI, will serve as a temporary voting member at the first meeting of the drugs, biologics and therapeutics panel of the Health Care Financing Administration's Medicare Coverage Advisory Committee (MCAC), scheduled for Sept. 15-16.

Artificial Embolization Device Downclassification Supported By Panel

Artificial embolization devices for neurological use should be downclassified to Class II, FDA's Neurological Devices Panel agreed at a June 12 meeting in Rockville, Maryland.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel